Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 44.22 USD 1.73% Market Closed
Market Cap: 4.1B USD
Have any thoughts about
Ultragenyx Pharmaceutical Inc?
Write Note

Intrinsic Value

RARE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RARE stock under the Base Case scenario is 63.72 USD. Compared to the current market price of 44.22 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 31%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RARE Intrinsic Value
63.72 USD
Undervaluation 31%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Ultragenyx Pharmaceutical Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
RARE
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for RARE cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about RARE?
Bearish
Neutral
Bullish

Fundamental Analysis

44.22 USD
+1.73%
+1.73%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Ultragenyx Pharmaceutical Inc
US
Biotechnology
Market Cap
4.1B USD
IPO
Jan 31, 2014
Employees
1 119
United States of America
Market Cap
4.1B USD
Industry
Biotechnology
IPO
Jan 31, 2014
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Ultragenyx Pharmaceutical Inc

Provide an overview of the primary business activities
of Ultragenyx Pharmaceutical Inc.

What unique competitive advantages
does Ultragenyx Pharmaceutical Inc hold over its rivals?

What risks and challenges
does Ultragenyx Pharmaceutical Inc face in the near future?

Has there been any significant insider trading activity
in Ultragenyx Pharmaceutical Inc recently?

Summarize the latest earnings call
of Ultragenyx Pharmaceutical Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ultragenyx Pharmaceutical Inc.

Provide P/S
for Ultragenyx Pharmaceutical Inc.

Provide P/E
for Ultragenyx Pharmaceutical Inc.

Provide P/OCF
for Ultragenyx Pharmaceutical Inc.

Provide P/FCFE
for Ultragenyx Pharmaceutical Inc.

Provide P/B
for Ultragenyx Pharmaceutical Inc.

Provide EV/S
for Ultragenyx Pharmaceutical Inc.

Provide EV/GP
for Ultragenyx Pharmaceutical Inc.

Provide EV/EBITDA
for Ultragenyx Pharmaceutical Inc.

Provide EV/EBIT
for Ultragenyx Pharmaceutical Inc.

Provide EV/OCF
for Ultragenyx Pharmaceutical Inc.

Provide EV/FCFF
for Ultragenyx Pharmaceutical Inc.

Provide EV/IC
for Ultragenyx Pharmaceutical Inc.

Show me price targets
for Ultragenyx Pharmaceutical Inc made by professional analysts.

What are the Revenue projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past Revenue estimates
for Ultragenyx Pharmaceutical Inc?

What are the Net Income projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past Net Income estimates
for Ultragenyx Pharmaceutical Inc?

What are the EPS projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past EPS estimates
for Ultragenyx Pharmaceutical Inc?

What are the EBIT projections
for Ultragenyx Pharmaceutical Inc?

How accurate were the past EBIT estimates
for Ultragenyx Pharmaceutical Inc?

Compare the revenue forecasts
for Ultragenyx Pharmaceutical Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ultragenyx Pharmaceutical Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ultragenyx Pharmaceutical Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ultragenyx Pharmaceutical Inc compared to its peers.

Compare the P/E ratios
of Ultragenyx Pharmaceutical Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ultragenyx Pharmaceutical Inc with its peers.

Analyze the financial leverage
of Ultragenyx Pharmaceutical Inc compared to its main competitors.

Show all profitability ratios
for Ultragenyx Pharmaceutical Inc.

Provide ROE
for Ultragenyx Pharmaceutical Inc.

Provide ROA
for Ultragenyx Pharmaceutical Inc.

Provide ROIC
for Ultragenyx Pharmaceutical Inc.

Provide ROCE
for Ultragenyx Pharmaceutical Inc.

Provide Gross Margin
for Ultragenyx Pharmaceutical Inc.

Provide Operating Margin
for Ultragenyx Pharmaceutical Inc.

Provide Net Margin
for Ultragenyx Pharmaceutical Inc.

Provide FCF Margin
for Ultragenyx Pharmaceutical Inc.

Show all solvency ratios
for Ultragenyx Pharmaceutical Inc.

Provide D/E Ratio
for Ultragenyx Pharmaceutical Inc.

Provide D/A Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Interest Coverage Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Altman Z-Score Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Quick Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Current Ratio
for Ultragenyx Pharmaceutical Inc.

Provide Cash Ratio
for Ultragenyx Pharmaceutical Inc.

What is the historical Revenue growth
over the last 5 years for Ultragenyx Pharmaceutical Inc?

What is the historical Net Income growth
over the last 5 years for Ultragenyx Pharmaceutical Inc?

What is the current Free Cash Flow
of Ultragenyx Pharmaceutical Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ultragenyx Pharmaceutical Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ultragenyx Pharmaceutical Inc

Current Assets 799.6m
Cash & Short-Term Investments 621.6m
Receivables 93.3m
Other Current Assets 84.7m
Non-Current Assets 738.8m
Long-Term Investments 203.1m
PP&E 272.4m
Intangibles 209.3m
Other Non-Current Assets 53.9m
Current Liabilities 285m
Accounts Payable 36m
Accrued Liabilities 195.5m
Other Current Liabilities 53.6m
Non-Current Liabilities 906.5m
Other Non-Current Liabilities 906.5m
Efficiency

Earnings Waterfall
Ultragenyx Pharmaceutical Inc

Revenue
522.7m USD
Cost of Revenue
-71.9m USD
Gross Profit
450.9m USD
Operating Expenses
-986.6m USD
Operating Income
-535.7m USD
Other Expenses
-23.2m USD
Net Income
-559m USD

Free Cash Flow Analysis
Ultragenyx Pharmaceutical Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RARE Profitability Score
Profitability Due Diligence

Ultragenyx Pharmaceutical Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Exceptional 1-Year Revenue Growth
25/100
Profitability
Score

Ultragenyx Pharmaceutical Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

RARE Solvency Score
Solvency Due Diligence

Ultragenyx Pharmaceutical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
51/100
Solvency
Score

Ultragenyx Pharmaceutical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc

Wall Street analysts forecast RARE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RARE is 94.28 USD with a low forecast of 48.48 USD and a high forecast of 147 USD.

Lowest
Price Target
48.48 USD
10% Upside
Average
Price Target
94.28 USD
113% Upside
Highest
Price Target
147 USD
232% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RARE?

Click here to dive deeper.

Dividends

Ultragenyx Pharmaceutical Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RARE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RARE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

RARE News

Other Videos

See Also

Discover More
What is the Intrinsic Value of one RARE stock?

The intrinsic value of one RARE stock under the Base Case scenario is 63.72 USD.

Is RARE stock undervalued or overvalued?

Compared to the current market price of 44.22 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 31%.

Back to Top